← All organizations
Highest phase reached
Phase 2
First clinical trial
Jun 1, 2011Last known activity
Aug 16, 2022
Timeline
2010s
- Jun 1, 2011
Bio-Path Holdings, Inc.— Founded
Drugs by trial phase (7 distinct, 6 trials)
Phase 2 (3 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Carcinoma, Ovarian Epithelial
- Endometrial Neoplasms
- Fallopian Tube Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, Mantle-Cell
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Myelodysplastic Syndromes
- Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Preleukemia
- Waldenstrom Macroglobulinemia
Recent trials (6)
- NCT05190471Lead sponsorPhase 1Aug 16, 2022
- NCT04196257Lead sponsorPhase 1Feb 29, 2020
- NCT04072458Lead sponsorPhase 1Nov 30, 2019
- NCT02923986Lead sponsorPhase 1/Phase 2Nov 1, 2016
- NCT02781883Lead sponsorPhase 2May 1, 2016
- NCT01159028Lead sponsorPhase 1Jun 1, 2010
Details
- Founded
- Houston, TX, US Jun 1, 2011
- Last known activity
- Aug 16, 2022